Despite a slow rise in the first 12 weeks, a significant decrease of CD19+ B lymphocyte count was observed at 48th week, consistent with previous studies of patients administered with Telitacicept in RA.26, 28. The gene discussed is CD19; the disease is rheumatoid arthritis.